Emerging therapeutic regimes for the management of mycetomas

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 12, 2008, Pages 2077-2085

  Ameen, Mahreen ^a   Arenas, Roberto ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

Author keywords

Actinomycetoma; Antibiotics; Antifungals; Eumycetoma; Mycetoma; Therapy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; COTRIMOXAZOLE; DAPSONE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; ITRACONAZOLE; KETOCONAZOLE; LINEZOLID; POSACONAZOLE; VORICONAZOLE;

ACTINOMYCETOMA; ADD ON THERAPY; ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ASPIRATION CYTOLOGY; BACTERIAL INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUMYCETOMA; HISTOPATHOLOGY; HUMAN; IMMUNODIFFUSION; IMMUNOELECTROPHORESIS; LONG TERM CARE; LYMPHEDEMA; MICROSCOPY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NOCARDIA BRASILIENSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POLYMERASE CHAIN REACTION; REVIEW; SUBCUTANEOUS NODULE; TREATMENT RESPONSE; X RAY;

ACTINOBACTERIA; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CARBAPENEMS; HUMANS; MADURELLA; MADUROMYCOSIS; OXAZOLIDINONES; TRIAZOLES;

EID: 50949104088     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.12.2077     Document Type: Review

References (74)

1. Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health 2002;7:788-92
2. Lupi O, Tyring SK, McGinnis MR. Tropical dermatology: fungal tropical diseases. J Am Acad Dermatol 2005;53:931-51
3. Welsh O, Vera-Cabrera L, Salinas-Carmona MC. Mycetoma. Dermatol Clin 2007;25(2):195-202
4. Ahmed AO, Mukhtar MM, Kool-Sijmons M, et al. Development of a species-specific PCR-restriction fragment length polymorphism analysis procedure for the identification of Madurella mycetomatis. J Clin Microbiol 1999;37:3175-8
5. Desnos-Ollivier M, Bretagne S, Dromer F, et al. Molecular identification of black-grain mycetoma agents. J Clin Microbiol 2006;44:3517-23
6. Van De Sande WW, Janse DJ, Hira V, et al. Translationally controlled tumour protein from Madurella mycetomatis, a marker for tumorous mycetoma progression. J Immunol 2006;177:1997-2005
7. Van De Sande WW, Fahal A, Verbrugh H, Van Belkum A. Polymorphisins in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immumol 2007;179(5):3065-74
8. Borman AM, Linton CJ, Miles SJ, Johnson EM. Molecular identification of pathogenic fungi. J Antimicrob Chemother 2008;61(Suppl 1):7-12
9. Rippon J. Mycetoma. In: Rippon J, editor, Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd edition. Philadelphia, PA: WB Saunders; 1998. p. 325-52
10. McGinnis MR, Padhye AA. Fungi causing eumycotic mycetoma. In: Murray PR, Baron EJ, Jorgensen JH, et al., editors, Manual of clinical microbiology. 7th edition. Washington, DC: American Society of Microbiology Press; 2003. p. 1848-56
11. Mariat F, Destombes P, Segretain G. The mycetomas: clinical features, pathology, etiology and epidemiology. Contrib Microbiol Immunol 1977;4:1-39
12. Lopez-Martinez R, Mendez-Tovar JL, Lavalle P, et al. Epidemiology of mycetoma in Mexico: study of 2,105 cases (in Spanish). Gac Med Mex 1992;128(4):477-81
13. Castro LG, Piquero-Casal J. Clinical and mycologic findings and therapeutic outcome of 27 mycetoma patients from São Paulo, Brazil. Int J Dermatol 2008;47(2):160-3
14. El Hag LA, Fahal AH, Khalil EAG. Fine needle aspiration cytology of mycetoma. Acta Cytol 1996;40(3):461-4
15. Padhye AA, McGinnis MR. Fungi causing eumycotic mycetoma. In: Murray PR, Baron EJ, Pfaller MA, et al. editors, Manual of clinical microbiology. 7th edition. Washington, DC: American Society of Microbiology Press; 1999. p. 1318-26
16. Joshi KR, Singhvi S. Serodiagnosis of mycetoma. Trans R Soc Trop Med Hyg 1988;82:334
17. Salinas-Carmona MC, Welsh O, Casillas SM. Enzyme-linked immunosorbent assay for serological diagnosis of Nocardia brasiliensis and clinical correlation with mycetoma infections. J Clin Microbiol 1993;31:2901-6
18. Salinas-Carmona MC. Anti-Nocardia brasiliensis antibodies in patients with actinomycetma and their clinical usefulness. Gac Med Mex 2001;137(1):1-8
19. Fahal AH, El Sheikh HA, El Lider MA, et al. Ultrasonic imagin in mycetoma. Br J Surg 1997;78:765-6
20. Fahal AH, Hassan MA. Mycetoma. Br J Surg 1992;79:1138-41
21. Fahal AH. Evidence based guidelines for mycetoma patients' management. 2000. Mycetoma Research Centre homepage. Available from: www.mycetoma.org
22. Del Giudice P. Treatment of eumycetoma. J Am Acad Dermatol 1998;39:137
23. Mahgoub ES. Medical management of mycetoma. Bull WHO 1976;54:3003-311
24. Welsh O, Salinas MC, Rodriquez MA. Treatment of eumycetoma and actinomycetoma. Curr Top Med Mycol 1995;6:47-71
25. Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg 1984;78:376-9
26. Venugopal PV, Venugopal TV. Treatment of eumycetoma with ketoconazole. Aust J Dermatol 1993;34:27-9
27. Poncio Mendes R, Negroni R, Bonifaz A, Pappagianis D. New aspects of some endemic mycoses. Med Mycol 2000;38(Suppl 1):237-41
28. Smith EL, Kutbi S. Improvement of eumyceroma with itraconazole. J Am Acad Dermatol 1997;34(2 Part 1):279-80
29. McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol. 1998;36:2353-5
30. Aluned AOA, Van De Sande WW, Van Vianen W. In vitro susceptibilities of Madurella mycetomatis to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-bis (2-methoxy-4-nitro-5- sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay. Antimicrob Agents Chemother 2004;48(7):2742-6
31. N'diaye B, Dieng MT, Perez A, et al. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol 2006;45:154-7
32. Lacroix C, De Kerviller E, Morel P, et al. Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermatol 2005;152:1067-8
33. Loulergue P, Hot A. Dannaoui E, et al. Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg 2006;75(6):1106-7
34. Schaenman JM, Digiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 2005;43:973-7
35. Porte L, Khatibi S, Hajj LE, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg 2006;100:891-4
36. Mouas H, Lutsar I, Dupont B, et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005;40:1141-7
37. Negroni R, Tobon A, Bustamante B, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 2005;47:339-46
38. Bonifaz A, Flores P, Saul A, et al. Treatment of actinomycetoma due to Nocardia spp. with amoxicillin-clavulanate. Br J Dermatol 2007;156(2):308-11
39. Welsh O, Sauceda E, Gonzalez J, Ocampo J. Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma. J Am Acad Dermatol 1987;17:443-8
40. Mahaisavariya P, Chaiprasert A, Sivayathorn A, Khemngern S. Deep fungal and higher bacterial skin infections in Thailand: clinical manifestations and treatment regimens. Int J Dermatol 1999;38:279-84
41. Gugnani HC, Suselan AV, Anikwe RM, et al. Actinomycetoma in Nigeria. J Trop Med Hyg 1981;84(6):259-63
42. Fahal AH. Mycetoma: a thorn in the flesh. Trans R Soc Trop Med Hyg 2004;98:3-11
43. Mahgoub ES. Treatment of actinomycetoma with sulphamethoxazole plus trimethoprim. Am J Trop Med Hyg 1972;21(3):332-5
44. Welsh O. Mycetoma. Current concepts in treatment. Int J Dermatol 1991;30:387-98
45. Dieng MT, Niang SO, Diop B, Ndiaye B. Actinomycetomas in Senegal. Study of 90 cases (in French). Bull Soc Pathol Exot Filiales 2005;98:18-20
46. Smego RA, Moeller MB, Gallis HA. Trimethoprim-sulfamedioxazole therapy for Nocardia infections. Arch Intern Med 1983;143:711-8
47. Ramam M, Bhat R, Garg T, et al. A modified two-step treatment for actinomycetoma. Indian J Dermatol Venereol Leprol 2007;73:235-9
48. Welsh O, Lopez R. Micetomas con diseminacion pulmonary (in Spanish). Med Cutan Ibero Lat Am 1985;13:517-23
49. Gombert ME, Aulicino TM. Synergism of imipenem and amilkacin in combination with other antibiotics against Nocardia asteroidcs. Antimicrob Agents Chemother 1983;24(5):810-1
50. Gomez-Flores A, Welsh O, Said-Fernández S, et al. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 2004;48(3):832-7
51. Wallace RJ, Nash DR, Johnson WK, et al. β-Lactam resistance in Nocardia brasiliensis is mediated by β-lactamase and reversed in presence of clavulanic acid. J Infect Dis 1987;156:959-66
52. Steingrube VA, Wallace RJ, Brown BA, et al. Acquired resistance of Nocardia brasiliensis to clavulanic acid related to a change in beta-lactamase following therapy with amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991;35:524-8
53. Baril L, Boiron P, Manceron V, et al. Refractory craniofacial actinomycetoma due to Streptomyces somaliensis that required salvage therapy with amikacin and imipenem. Clin Infect Dis 1999;29(2):460-1
54. Khardori N, Shawar R, Gupta R, et al. In vitro antimicrobial susceptibilities of Nocardia species. Antimicrob Agents Chemother 1993;37(4):882-4
55. Kashima M, Kano R, Mikami Y, et al. A successfully treated case of mycetoma due to Nocardia veterana. Br J Dermatol 2005;152(6):1349-52
56. McNeil MM, Brown JM, Jarvis WR, Ajello L. Comparison of species distribution and antimicrobial susceptibility of aerobic actinomycetes from clinical specimens. Rev Infect Dis 1990;12:778-83
57. Kageyama A, Hoshino Y, Watanabe M, et al. Clinical isolates of Nocardia brasiliensis from Japan exhibit variable susceptibility to the antibiotic imipenem. Mycopathologia 2004;158(3):275-8
58. Fernandez RF, Arenas R, Reyes M, Zacarias R. Micetoma dorsal por Nocardia brasiliensis. Comunicacion de un caso curado con imipenem y amikacina (in Spanish). Dermatol Rev Mex 2005;49:178-81
59. Fuentes A, Arenas R, Reyes M, et al. Actinomycetoma and Nocardia sp. Report of five cases treated with imipenem, or imipenem plus amikacin (in Spanish). Gac Med Mex 2006; 142:247-52
60. Fernandez RF, Arenas R: Imipenem. An alternative treatment for actinomycetoma: an appraisal (in Spanish). Monogr Dermatol 2006;19:48-54
61. Chaudhuri BN, Maiti PK, Sil J. Antibiotic sensitivity patterns of actinomycetes isolated from patients with actinomycetomas. Indian J Med Res 1997;105:162-6
62. Vera-Cabrera L, Gomez-Flores A, Escalante-Fuentes WG, Welsh O. In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis. Antimicrob Agents Chemother 2001;45:3629-30
63. Brown-Elliott BA, Ward SC, Crist CJ, et al. In vitro activities of linezolid against multiple Nocardia species.Antimicrob Agents Chemother 2001;45:1295-7
64. Moylett EH, Pacheco SE, Brown-Elliott BA, et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003;36:313-8
65. Vera-Cabrera L, Gonzalez E, Rendon A, et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother 2006;50(9):3170-2
66. Espinoza-González MA, Welsh O, De Torres NW, et al. Efficacy of DA-7218, a new oxazolidinone prodrug, in the treatment of experimental actinomycetoma produced by Nocardia brasiliensis. Molecules 2008;13(1):31-40
67. Daw-Garza A, Welsh O, Said-Fernández S, et al. In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. Antimicrob Agents Chemother 2008;52(4):1549-50
68. Ahmed AO, Abugroun ES. Unexpected high prevalence of secondary bacterial infection in patients with mycetoma. J Clin Microbiol 1998;36:850-1
69. Gunduz Y, Orgue S, Demireli P, et al. A case of mycetoma successfully treated with itraconazole and co-trimoxazole. Mycoses 2006;49:436-8
70. Fahal AH, Hassan MA, Sanhouri M. Surgical treatment of mycetoma. Sudan Med J 1994;32:98-104
71. Bonifaz A, Ibarra G, Saul A, et al. Mycetoma in children: experience with 15 cases. Pediatr Infect Dis J 2007;26(1):50-2
72. Bonifaz A, Ibarra G, Saul A, et al. Actinomycetoma in children and adults (in Spanish). Monograf Dermatol 2006;19(1):17-23
73. Stefano PC, Noriega AL, Kobrin AL, et al. Primary cutaneous nocardiosis in immunocompetent children. Eur J Dermatol 2006;16(4):406-8
74. Nolt D, Wadowsky RM, Green M. Lymphocutaneous Nocardia brasiliensis infection: a pediatric case cured with amoxicilin/clavulanate. Pediatr Infect Dis J 2000;19(10):1023-5